HUNK and breast cancer: Taken together, our results indicate HUNK inhibition using a pharmacological inhibitor may be a novel therapeutic approach for HER2+ breast cancer and that targeting HUNK in conjunction with HER2 inhibition will be beneficial for the treatment of refractory HER2+ breast cancer.